By Sherri Oslick --
About
Court Report: Each week we will report briefly on recently filed
biotech and pharma cases, and a few interesting cases will be selected
for periodic monitoring.
Teva Pharmaceutical Industries Ltd. et. al. v. Cobalt Pharmaceuticals, Inc. et. al.
2:07-cv-01690; filed April 10, 2007 in the District Court of New Jersey
Infringement of U.S. Patent Nos. 6,600,073 ("Methods for Preparation of Sertraline Hydrochloride Polymorphs," issued July 29, 2003), 6,500,987 ("Sertraline Hydrochloride Polymorphs," issued December 31, 2002), 6,495,721 ("Sertraline Hydrochloride Form II and Methods for the Preparation Thereof," issued December 17, 2002), and 6,897,340 ("Processes for Preparation of Polymorphic Form II of Sertraline Hydrochloride," issued May 24, 2005), all directed to methods of manufacturing crystalline forms of sertraline hydrochloride (the API in Pfizer's Zoloft®, used to treat depression) based on defendant's manufacture and sale of generic Zoloft®. View the complaint here.
Monsanto Co. et. al. v. Bening et. al.
3:07-cv-00261; filed April 9, 2007 in the Southern District of Illinois
Infringement of U.S. Patent Nos. 5,352,605 ("Chimeric Genes for Transforming Plant Cells Using Viral Promoters," issued October 4, 1994) and RE39,247 ("Glyphosate-tolerant 5-enolpyruvylshikimate-3-phosphate Synthases," issued August 22, 2006) based on defendants' use of soybean seed produced from earlier planted Roundup Ready® soybean seed. View the complaint here.
AstraZeneca Pharmaceuticals LP et. al. v. Sandoz Inc.
3:07-cv-01632; filed April 6, 2007 in the District Court of New Jersey
Infringement of U.S. Patent No. 4,879,288 ("Novel Dibenzothiazepine Antipsychotic," issued November 7, 1989) following a paragraph IV certification as part of Sandoz's filing of an ANDA to manufacture a generic version of AstraZeneca's Seroquel® (quetiapine fumarate, used to treat schizophrenia and bipolar disorder). View the complaint here.
Merck Sharp & Dohme Pharmaceuticals Srl v. Teva Pharmaceuticals USA, Inc. et. al.
3:07-cv-01596; filed April 3, 2007 in the District Court of New Jersey
Infringement of U.S. Patent No. 5,565,473 ("Unsaturated Hydroxyalkylquinoline Acids as Leukotriene Antagonists," issued October 15, 1996) following Teva's filing of an ANDA to manufacture a generic version of Merck's Singulair® (montelukast sodium, used to treat asthma and allergic rhinitis). View the complaint here.
LBS Technologies, Inc. v. Incyte Corp.
2:07-cv-01297; filed March 30, 2007 in the Eastern District of Pennsylvania
Infringement of U.S. Patent Nos. 5,021,335 ("In Situ Transcription in Cells and Tissues," issued June 4, 1991), 5,168,038 (same title, issued December 1, 1992), 5,545,522 ("Process for Amplifying a Target Polynucleotide Sequence Using a Single Primer-Promoter Complex," issued August 13, 1996), 5,716,785 ("Processes for Genetic Manipulations Using Promoters," issued February 10, 1998), 5,891,636 (same title, issued April 6, 1999), 5,958,688 ("Characterization of mRNA patterns in neurites and single cells for medical diagnosis and therapeutics," issued September 28, 1999), and 6,291,170 ("Multi-Genes Expression Profile," issued September 18, 2001). View the complaint here.
Comments